Evan Rogers - Concepedia

Author

Evan Rogers

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

E. Rogers, Evan Rogers

Publications

798

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Fate Therapeutics (United States)Seoul National University Hospital Massachusetts General Hospital

About

Evan Rogers is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	194
2	Cell Biology	5	5	165
3	Health Sciences	2	2	32
4	Natural Sciences	1	1	28
5	Biomolecular Engineering	1	1	12

Evan Rogers

Publications

741

Citations

H-Index

Page 1

	Year	Citations
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho, Cancer Discovery	2018	463
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations Brion W. Murray, Dayong Zhai, Wei Deng, Molecular Cancer Therapeutics	2021	84
TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers Alexander Drilon, Evan Rogers, Dayong Zhai, Annals of Oncology Tumor BiologyOncologyPotent Ret/src InhibitorMedicineAnti-cancer Agent	2019	55
The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models. Alexander Drilon, Dayong Zhai, Evan Rogers, Journal of Clinical Oncology Selective Ret InhibitorsRet FusionsCancer BiologyTumor BiologyTumor Immunity	2020	50
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants J. Jean Cui, Dayong Zhai, Wei Deng, European Journal of Cancer Novel Alk/ros1/trk InhibitorSignal TransductionSignaling PathwayTrka G595r MutantsMolecular Biology	2016	29
Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations Alexander Drilon, Dayong Zhai, Wei Deng, Cancer Research Molecular BiologyMultiple Cancer TypesAbstract 442Chemical BiologyCancer Biology	2019	28
Abstract 5226: TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors J. Jean Cui, Evan Rogers, Dayong Zhai, Cancer Research Alk Resistant MutationsPharmacotherapyCancer BiologyTumor BiologyDrug Resistance	2020	20
Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors Dayong Zhai, Wei Deng, Zhongdong Huang, Cancer Research Src KinaseDrug TargetAbstract 2132Current Alk InhibitorsPharmacotherapy	2016	12

Page 1